Soleno Therapeutics Investors to Consider Class Action Amid Allegations of Misleading Safety Data

Background on Soleno Therapeutics

Soleno Therapeutics, Inc. has been under scrutiny following significant allegations regarding its leading product, VYKAT™ XR, aimed at treating Prader-Willi syndrome (PWS). Investors who acquired shares between March and November 2025 are now facing uncertainties. Hagens Berman, a renowned rights law firm, has stepped in to advocate for these affected investors, reminding them of the upcoming May 5, 2026, deadline to become lead plaintiffs in a potential class action lawsuit.

Details of the Allegations

The core of the allegations against Soleno revolves around the company's supposed misrepresentation of its product's safety and efficacy. Claims have emerged that Soleno failed to disclose critical safety risks tied to VYKAT™ XR, including troubling evidence of heart-related issues in children using this medication. Investor trust has been shaken by the assertion that the company downplayed safety concerns, contributing to the tarnishing of its public image.

Various reports, notably from Scorpion Capital, have raised red flags, indicating issues with the integrity of clinical trial data. This includes reliance on a physician known for questionable practices, potentially leading to mistrust in the data presented by Soleno. Furthermore, the firm's claims regarding the commercial success of VYKAT™ XR have been challenged, suggesting that the reported metrics were inflated and possibly influenced by external factors not reflective of genuine market demand.

Stock Reactions and Market Impact

The fallout from these revelations has been stark. Following the publication of Scorpion Capital's report on August 15, 2025, which detailed alarming patient reactions and triggered a sharp decline in stock value, investors felt the immediate brunt of the situation. The stock experienced further turmoil when the company announced its Q3 2025 results, revealing a disruption in DCCR's launch and a stark drop in patient enrollments, leading to a dramatic 27% plunge in stock prices in just a day.

Legal Implications and Next Steps

With the potential class action, the legal framework is focused on the claims that Soleno Therapeutics neglected critical safety measures in managing its product's launch. Reed Kathrein of Hagens Berman has emphasized the importance of the case, highlighting the necessity for corporate accountability in ensuring the safety and efficacy of medical treatments.

Investors are urged to act quickly; those who purchase shares in the indicated time frame and experienced notable losses must submit their claims before the May 5 deadline. The firm is also calling on whistleblowers with non-public information tied to Soleno to contribute to the investigation, offering incentives under the SEC Whistleblower Program for actionable insights.

About Hagens Berman

Hagens Berman is not just advocating for investors but is a leading law firm that embodies the spirit of corporate accountability. With a rich history of securing over $2.9 billion for various clients adversely affected by corporate transgressions, the firm represents investors, workers, consumers, and whistleblowers alike. By continuously fighting for the rights of those exploited by negligent or dishonest corporate practices, Hagens Berman staunchly upholds the principles of justice in the financial realm.

Conclusion

As the situation with Soleno Therapeutics develops, it stands as a poignant reminder of the volatility in the pharmaceutical market and the paramount importance of transparency. Investors must stay vigilant and proactive, particularly in circumstances surrounding class action lawsuits focused on corporate responsibility and consumer safety. For those affected by the alleged practices of Soleno Therapeutics, now is the moment to act.